Myelofibrosis drug combo trial halted early – what we know

NCT ID NCT06245941

First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 21 times

Summary

This study tested a combination of two experimental drugs, TQ05105 and TQB3909, in 21 adults with moderate- to high-risk myelofibrosis, a rare bone marrow disorder. The goal was to find the safest dose and see if the combo could shrink an enlarged spleen by at least 35% after 24 weeks. The trial was terminated early, so final results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hennan Cancer Hospital

    Zhengzhou, Henan, 450003, China

  • People's Hospital of Tianjin

    Tianjin, Tianjin Municipality, 300122, China

  • The First Affiliated Hospital Zhejiang University School Of Medicine

    Hangzhou, Zhejiang, 310003, China

  • The Second People's Hospital of Hefei

    Hefei, Anhui, 230012, China

  • Xijing Hospital of the Fourth Military Medical University

    Xi'an, Shaanxi, 710032, China

Conditions

Explore the condition pages connected to this study.